Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...

Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...

Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine PRESS RELEASE Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine Swiss regulatory authorities, including the Swiss Agency for Therapeutic...

Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...

Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...